Dong-A to conduct phase 3 study for Zydena in US
Published: 2009-11-09 06:58:00
Updated: 2009-11-09 06:58:00
Dong-A Pharmaceutical Co., says it will carry out its Phase 3 multicenter study in the United States, designed to investigate the efficacy and safety of Zydena (udenafil) in 1,120 patients with erectile dysfunction after completing Phase II.
"We are extremely pleased with the results of this 3...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
